Parabilis Medicines, Inc.
PBLSNext catalyst
FOG-001
Cancer
Get an email about PBLS's next catalysts
Track Parabilis Medicines (PBLS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
FOG-001 Phase 2 Est. Readout
Estimated primary completion for FOG-001 trial (NCT05919264) in Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Parabilis Medicines, Inc.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in Parabilis Medicines, Inc.'s (PBLS) pipeline across Phase 2. Its lead program is FOG-001 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Parabilis Medicines, Inc.'s next FDA catalyst?β
Parabilis Medicines, Inc.'s (PBLS) next tracked catalyst is a Phase 2 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PBLS biotech catalysts?β
Add PBLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Parabilis Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
